Table 4 Medications.
From: Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes
CD patients (n = 31) | Controls (n = 124) | p-value | |
|---|---|---|---|
Azithromycin | 23 (74.2%) | 91 (73.4%) | > 0.999 |
Clarithromycin | 1 (3.2%) | 17 (13.7%) | 0.126 |
Chloroquine | 0 (0.0%) | 1 (0.8%) | > 0.999 |
Hydroxycloroquine | 1 (3.2%) | 5 (4.0%) | > 0.999 |
Remdesivir | 0 (0.0%) | 2 (1.6%) | > 0.999 |
Anticoauglation | |||
Profilatic | |||
Low-molecular-weight | 16 (51.6%) | 65 (52.4%) | > 0.999 |
Non-fractioneted | 11 (35.5%) | 58 (46.8%) | 0.353 |
Fondaparinoux | 0 (0.0%) | 1 (0.8%) | > 0.999 |
Therapeutic | 0 (0.0%) | 1 (0.8%) | > 0.999 |
Low-molecular-weight | 5 (16.1%) | 8 (6.5%) | 0.138 |
Non-fractioneted | 1 (3.2%) | 5 (4.0%) | > 0.999 |
